Carcinoma, Non-Small-Cell Lung
Showing NaN - NaN of 59
NSCLC, Tumor Metastasis Trial in Worldwide (LY3537982, Pembrolizumab, Placebo)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- Neoplasm Metastasis
- LY3537982
- +5 more
-
Tucson, Arizona
- +217 more
Nov 1, 2023
NSCLC Trial in Korea, Republic of, Malaysia, United States (Cetrelimab, Amivantamab)
Recruiting
- Carcinoma, Non-Small-Cell Lung
-
Fairfax, Virginia
- +3 more
Jun 16, 2023
NSCLC Trial in Worldwide (Lazertinib, Amivantamab, Carboplatin)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Lazertinib
- +3 more
-
Los Angeles, California
- +83 more
Jan 31, 2023
NSCLC Trial in Worldwide (Amivantamab, Pemetrexed, Carboplatin)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Amivantamab
- +2 more
-
Duarte, California
- +228 more
Jan 31, 2023
NSCLC Trial in Japan, Korea, Republic of, Singapore (capmatinib, pemetrexed, cisplatin)
Terminated
- Carcinoma, Non-Small-Cell Lung
- capmatinib
- +4 more
-
Kashiwa, Chiba, Japan
- +3 more
Jan 31, 2023
NSCLC Trial in Worldwide (Alectnib, Cisplatin, Vinorelbine)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Alectnib
- +5 more
-
Chicago, Illinois
- +140 more
Jan 20, 2023
KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, NSCLC Trial (JDQ443, trametinib, Ribociclib)
Recruiting
- KRAS G12C Mutant Solid Tumors
- +10 more
- JDQ443
- +3 more
-
Boston, Massachusetts
- +5 more
Jan 11, 2023
NSCLC Trial in Worldwide (Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Docetaxel)
Completed
- Carcinoma, Non-Small-Cell Lung
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
- Docetaxel
-
Beijing, China
- +37 more
Jan 9, 2023
NSCLC Trial in Worldwide (INC280 (capmatinib))
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- INC280 (capmatinib)
-
Long Beach, California
- +95 more
Dec 29, 2022
NSCLC Trial in Worldwide (Selpercatinib, Placebo)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Selpercatinib
- Placebo
-
Santa Monica, California
- +206 more
Dec 27, 2022
NSCLC Trial in Worldwide (Durvalumab, Placebo, Osimertinib (single-arm, open-label))
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Durvalumab
- +2 more
-
Tuscaloosa, Alabama
- +260 more
Dec 16, 2022
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Worldwide
Active, not recruiting
- RET-altered Non Small Cell Lung Cancer
- +39 more
- pralsetinib (BLU-667)
-
Phoenix, Arizona
- +65 more
Nov 10, 2022
Tumors, NSCLC, Pancreatic Tumors Trial in Worldwide (V941, Pembrolizumab)
Completed
- Neoplasms
- +3 more
- V941
- Pembrolizumab
-
Gilbert, Arizona
- +25 more
Sep 5, 2022
Korea Osimertinib Real World Evidence Study to Assess Safety and
Recruiting
- Carcinoma, Non-Small-Cell Lung
-
Busan, Korea, Republic of
- +10 more
Aug 18, 2022
Lung Tumors, NSCLC Trial in Worldwide (biological, drug, radiation)
Recruiting
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Pembrolizumab
- +9 more
-
Mobile, Alabama
- +194 more
Aug 18, 2022
NSCLC Trial in Worldwide (Amivantamab, Osimertinib, Lazertinib)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Amivantamab
- +3 more
-
Goodyear, Arizona
- +266 more
Aug 17, 2022
NSCLC Trial in Worldwide (Lazertinib, Amivantamab, Pemetrexed)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Lazertinib
- +3 more
-
Phoenix, Arizona
- +303 more
Aug 17, 2022
NSCLC Trial in Worldwide (Capmatinib, Amivantamab)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
-
Orange, California
- +40 more
Aug 3, 2022
NSCLC Trial in Worldwide (Durvalumab + SoC chemo, Placebo + SoC chemo)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Durvalumab + SoC chemotherapy
- Placebo + SoC chemotherapy
-
Birmingham, Alabama
- +147 more
Aug 1, 2022
KRAS G12C Mutant Solid Tumors, NSCLC, Carcinoma, Colorectal Trial in Worldwide (JDQ443, TNO155, tislelizumab)
Recruiting
- KRAS G12C Mutant Solid Tumors
- +9 more
- JDQ443
- +2 more
-
Atlanta, Georgia
- +31 more
Jul 7, 2022
NSCLC, Immune Checkpoint Inhibitors Trial in Seoul (F-18 FDG PET/CT)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Immune Checkpoint Inhibitors
- F-18 FDG PET/CT
-
Seoul, Korea, Republic ofSamsung Medical Center
Jun 15, 2022
NSCLC Trial in Worldwide (Lorlatinib, Crizotinib)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
-
Altamonte Springs, Florida
- +164 more
May 27, 2022